Zobrazeno 1 - 10
of 256
pro vyhledávání: ''
Autor:
Oscar Fernandez
Publikováno v:
Multiple Sclerosis and Related Disorders. 17:75-83
Background Aggressive, highly active, or rapidly evolving severe relapsing-remitting multiple sclerosis (RRMS) is characterized by frequent relapses and active disease on magnetic resonance imaging, ultimately leading to a high risk for rapid disabil
Publikováno v:
Acta Neurologica Belgica
Patients with unknown time of stroke onset (UOS) represent around one-third of ischemic stroke patients. These are patients with wake-up stroke (WUS) or daytime-unwitnessed stroke (DUS), often presenting outside the time-window for reperfusion therap
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 18:576-582
Nocebo is very prevalent among neurological disorders, resulting in low adherence and treatment outcome. We sought to examine the AEs following placebo administration in placebo-controlled randomised clinical trials (RCTs) for motor neuron disease (M
Autor:
Stanley Cohan, Sharon G. Lynch, Jacob Elkins, Wanda Castro-Borrero, Katherine Riester, Guido Sabatella, Ping Wang, Ralph H.B. Benedict
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Cognitive impairment is common in multiple sclerosis (MS), with cognitive processing speed being the most frequently affected domain. Objective: Examine the effects of daclizumab beta versus intramuscular (IM) interferon (IFN) beta-1a on
Autor:
Craig M. Zaidman, Kush Kapur, Sung Yim, Jim S. Wu, Tim Harrington, Amy Pasternak, Seward B. Rutkove, Heather Szelag, Lavanya Madabusi, Adam Pacheck, Basil T. Darras
Publikováno v:
Annals of Neurology. 81:622-632
Objective: Sensitive, objective and easily applied methods for evaluating disease progression and response to therapy are needed for clinical trials in Duchenne muscular dystrophy (DMD). In this study, we evaluated whether electrical impedance myogra
Autor:
Bernhard Landwehrmeyer, John H. Warner, Douglas R. Langbehn, Jane S. Paulsen, Sarah J. Tabrizi, Jeffrey D. Long, Cristina Sampaio
Publikováno v:
Movement Disorders. 32:256-263
Background Characterizing progression in Huntington's disease is important for study the natural course and selecting appropriate participants for clinical trials. Objectives The aim was to develop a prognostic index for motor diagnosis in Huntington
Autor:
Rosa M. Tolón, Silvia Ortega-Gutiérrez, M. A. Alonso Alonso Arias, Javier Ruiz, Ismael Galve-Roperh, María Laura García-Bermejo, Carolina Ruiz Romero, María Jesús García de Yébenes, Sara Valdeolivas, Guillermo García Ribas, Eva Resel, Manuel Guzmán, Justo García de Yébenes Prous, Patricia Trigo Cubillo, Jose Luis López-Sendón Moreno, Onintza Sagredo, Juan García Caldentey
Publikováno v:
Journal of Neurology. 263:1390-1400
Huntington's disease (HD) is a neurodegenerative disease for which there is no curative treatment available. Given that the endocannabinoid system is involved in the pathogenesis of HD mouse models, stimulation of specific targets within this signali
Autor:
Patrick Vermersch, E. Sartori, Benoit Dupuy, Philippe Cabre, Marc Debouverie, David Brassat, Patrick Hautecoeur, Jérôme De Seze, Jean Pelletier, Pierre Clavelou, Irène Coman, Christian Creveuil, Pierre Lebiez, Ayman Tourbah, Olivier Heinzlef, Gilles Defer, Bruno Brochet, Christine Lebrun-Frenay, David Daplaud, Laure Peyro Saint Paul, Giovanni Castelnovo
Publikováno v:
Journal of the Neurological Sciences. 363:69-76
Memantine, an uncompetitive antagonist of N-methyl- d -aspartate (NMDA)-type glutamate receptors that was approved for the treatment of moderate to severe Alzheimer's disease, has been negatively evaluated for the treatment of cognitive disorders of
Autor:
Bhupendra Khatri
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 9 (2016)
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This revie
Publikováno v:
Translational Stroke Research. 7:261-273
Stroke is the second leading cause of death worldwide, and differences between men and women have been documented in incidence, prevalence, and outcome. Here, we reviewed the literature on sex differences in stroke severity, mortality, functional out